Evaxion A/S ADR EVAX

$3.00 +0.24 (8.70%)

Valuation

Market cap
27,064,000
Revenue TTM
$7,530,000
Net income TTM
$-7,710,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-102.39%
Debt to equity
0.56

Trading

Volume
184,200
Avg volume
84,048
Day's range
$2.71 – $3.21
Shares out
9,021,000
Stochastic %K
55%
Beta
0.60
Analysts
Strong Buy
Price target
$12.25

Price

Company profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs...

Show more

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Industry
Biotechnology
Sector
Healthcare
Phone
45 53 53 18 50
Website
https://evaxion.ai
Address
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark

Latest news

Stocktwits

Ian_FV Nov 7, 12:27 AM
6-K/8-K Important Update $EVAX Evaxion A/S reported phase 2 trial results for its personalized cancer vaccine EVX-01, showing a 75% Objective Response Rate (ORR) in advanced melanoma patients, with sustained clinical and T-cell responses over three years. The findings, presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, demonstrate the vaccine's strong immune response and the 89% predictive accuracy of Evaxion's AI-Immunology platform in identifying vaccine targets. More details at www.ianfv.com
0 replies
STACKD0E Nov 6, 9:00 PM
👁 $BRVE $EVAX $INKT $NXPL $HALO
0 replies
Rayvio_News_Filter Nov 6, 4:02 PM
$EVAX 🏥 Evaxion A/S announces new phase 2 biomarker data from its personalized cancer vaccine EVX-01 in advanced melanoma, with ex vivo detection of neoantigen-specific T cells indicating strong EVX-01-induced immune responses. Selected from hundreds of headlines
0 replies
AlertsAndNews Nov 6, 4:01 PM
$EVAX headline just out here New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
1 replies
CydoniaAnhedonia Nov 5, 7:22 PM
$EVAX Picked up a few today. Still have faith in this company
0 replies
Manwiththeplan Nov 5, 7:04 PM
$EVAX less Trump is good for vaccine companies
0 replies
NoNoNoNoNoNoYesNo Nov 5, 3:16 PM
$EVAX aaaannndddd...we're f'd. That 40k bid at 2.85 got filled. No floor remains. I imagine this will be shorted to low/mid 2's from here.
0 replies
SkywalkerAR Nov 3, 10:36 AM
$EVAX https://www.linkedin.com/safety/go/?url=https%3A%2F%2Fevaxion%2Eai%2Finvestors%2Fevents-presentations%2Fwebinar-evx-01-phase-2-three-year-clinical-and-immune-data-from-a-personalized-neoantigen-cancer-vaccine%2F&urlhash=eajP&mt=QeJ9W8_7TSQPjkFKqlYgmF_lTIIesyopJuIssZUJQVOBq1uIJvUEjcZyotxOmF3YiuEsyZ6BE8ZHvrt3hriNZ40PRYXz10djCJQm1hibCCuTsLc8Twt8LmlNOemwxLeYM1K_ZZXJWYFvlEmTWzEPkIxRuV6xE46Lt1LkS96JdBftCQj9vzMbJre7P7uKbKahTYDcX-ObphVIClo&isSdui=true
0 replies